Indoleamine-pyrrole 2,3-dioxygenasemight be a prognostic biomarker for patients with renal cell carcinoma

Journal of Central South University (Medical Sciences)

Volumn 37, Issue 7, 2012, Pages 649-655

  Yuan, Fang ^a   Liu, Yinghong ^a   Fu, Xiao ^a   Chen, Junxiang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

3 dioxygenase; Endothelial cell; Indoleamine pyrrole 2; Prognostic biomarker; Renal cell carcinoma

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; MESSENGER RNA; TUMOR MARKER;

ARTICLE; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METABOLISM; MIDDLE AGED; NEPHRECTOMY; PATHOLOGY; PROGNOSIS;

CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; PROGNOSIS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84866054846     PISSN: 16727347     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1672-7347.2012.07.001     Document Type: Article

References (28)

1. Boon T, van der BP. Human tumor antigens recognized by T lymphocytes[J].J Exp Med, 1996, 183(3):725-729. (Pubitemid 26113944)
2. Lennerz V, Fatho M, Gentilini C, et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens[J]. Proc Natl Acad Sci USA, 2005, 102(44): 16013-16018. (Pubitemid 41552859)
3. van der BP, Van den Eynde BJ. Processing and presentation of tumor antigens and vaccination strategies[J]. Curr Opin Immunol, 2006, 18( 1): 98-104.
4. Heinemann D, Smith PJ, Symes MO. Expression of histocompatibility antigens and characterisation of mononuclear cell infiltrates in human renal cell carcinomas[J]. BrJ Cancer, 1987, 56(4): 433-437. (Pubitemid 17146346)
5. Brasanac D, Markovic-Lipkovski J, Hadzi-Djokic J, et al. Immunohistochemical analysis of HLA class II antigens and tumor infiltrating mononuclear cells in renal cell carcinoma: correlation with clinical and histopathological data[J]. Neoplasma, 1999, 46(3): 173-178. (Pubitemid 29398317)
6. Van den Hove LE, Van Gool SW, Van Poppel H, et al. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma[J]. Clin Exp Immunol, 1997, 109(3): 501-509. (Pubitemid 27402320)
7. Malinowski K, Kono K, Takayama T, et al. Inhibition of lymphocyte proliferative responses by renal cell carcinoma extract[J]. Transplant Proc, 1997, 29(1/2): 839-841. (Pubitemid 27125985)
8. Shabtai M, Ye H, Kono K, et al. Immune inhibitory effects of renal cell carcinoma extract on lectin and alloantigen-induced peripheral blood and tumor infiltrating lymphocyte histogenesis[J]. Urol Oncol, 2003, 21(1): 27-32. (Pubitemid 41115112)
9. Wang Q, Redovan C, Tubbs R, et al. Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes[J]. Int J Cancer, 1995, 61( 6): 780-785.
10. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas(Apo-l/CD95) ligand: implications for tumor immune escape[J]. Science, 1996, 274(5291): 1363-1366. (Pubitemid 26391458)
11. Kammerer R, Riesenberg R, Weiler C, et al. The tumour suppressor gene CEACAM1 is completely but reversibly downregulated in renal cell carcinoma[J]. J Pathol, 2004, 204(3): 258-267. (Pubitemid 39430084)
12. Ergun S, Tilki D, Oliveira-Ferrer L, et al. Significance of vascular stabilization for tumor growth and metastasis[J]. Cancer Lett,2006, 238(2): 180-187. (Pubitemid 43867907)
13. Oliveira-Ferrer L, Tilki D, Ziegeler G, et al. Dual role of carcinoembryonic antigen-related cell adhesion molecule 1 in angiogenesis and invasion of human urinary bladder cancer[J]. Cancer Res, 2004, 64(24): 8932-8938. (Pubitemid 39665500)
14. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic[J], Nat Med, 2003, 9(5): 713-725. (Pubitemid 36749220)
15. Dudderidge TJ, Stoeber K, Loddo M, et al. Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma[J]. Clin Cancer Res, 2005, 11 (7): 2510-2517. (Pubitemid 40569447)
16. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogenic fetal rejection by tryptophan catabolism[J]. Science, 1998, 281(5231): 1191-1193. (Pubitemid 28406294)
17. Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation[J]. Immunol Today,1999, 20(6): 469-473. (Pubitemid 29476077)
18. Osaki T, Oyama T, Gu C, et al. Prognostic impact of micrometastatic tumor cells in the lymph nodes and bone marrow of patients with completely resected Stage I non-small cell lung cancer[J]. J Clin Oncol, 2002, 20(13): 2930-2936. (Pubitemid 34728886)
19. Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase[J]. Nat Med, 2003, 9(10): 1269-1274. (Pubitemid 37279849)
20. Okamoto A, Nikaido T, Ochiai K, et al. Indoleamine 2, 3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer Cells[J]. Clin Cancer Res, 2005, 11(16): 6030-6039. (Pubitemid 41170335)
21. Ino K, Yoshida N, Kajiyama H, et al. Indoleamine 2, 3-dioxygenase is a novel prognostic indicator for endometrial cancer[J]. Br J Cancer, 2006, 95(11): 1555-1561. (Pubitemid 44863359)
22. Brandacher G, Perathoner A, Ladurner R, et al. Prognostic value of indoleamine 2, 3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T Cells[J]. Clin Cancer Res, 2006, 12(4): 1144-1151. (Pubitemid 43342502)
23. Sakurai K, Enomoto K, Amano S, et al. Study of indoleamine 2, 3-dioxygenase expression in patients of esophageal squamous cell carcinoma [J]. Gan To Kagaku Ryoho, 2004, 31 ( 11) : 1780-1782.
24. Astigiano S, Morandi B, Costa R, et al. Eosinophil granulocytes account for indoleamine 2, 3-dioxygenase-mediated immune escape in human non-small cell lung cancer[J]. Neoplasia, 2005, 7(4): 390-396. (Pubitemid 40664228)
25. Ishio T, Goto S, Tahara K, et al. Immunoactivative role of indoleamine 2, 3-dioxygenase in human hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2004, 19(3): 319-326. (Pubitemid 38338742)
26. Friberg M, Jennings R, Alsarraj M, et al. Indoleamine 2, 3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection[J]. Int J Cancer, 2002, 101(2): 151-155. (Pubitemid 34970907)
27. Muller AJ, Scherle PA. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors [J]. Nat Rev Cancer, 2006, 6(9): 613-625. (Pubitemid 44140859)
28. Hou DY, Muller AJ, Sharma MD,et al. Inhibition of indoleamine 2, 3-dioxygenase in dendritic cells by stereoisomers of 1-methyltryptophan correlates with antitumor responses[J]. Cancer Res,2007, 67(2): 792-801. (Pubitemid 46192220)